Ophtim 0.25%

Quick links to important sections

Ophtim 0.25%

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ophtim 0.25%

Ophtim 0.25% is a prescription-only ophthalmic medication designed to help manage the internal pressure balance of the eye. Its core component is Timolol Maleate, a widely recognized synthetic active substance.

Property Description
Active Ingredient Timolol Maleate (INN)
Form Sterile Ophthalmic Solution (Liquid)
Pharmacological Class Non-Selective Beta-Blocker
Rx Status Prescription-only (Rx)
Origin Synthetic Compound

What Type of Medicine is Ophtim 0.25%?

Ophtim 0.25% is classified as a non-selective beta-adrenergic blocking agent, commonly known as a beta-blocker. This pharmacological class is clinically recognized for its ability to regulate the fluid dynamics within the eye.

As a foundational medication in eye care, it operates by targeting and blocking specific nerve receptors, which effectively slows the rate at which fluid is produced inside the eye. This action helps to consistently maintain a healthy internal eye pressure. This drug is often used alone or in combination with other types of eye drops for patients who require enhanced fluid management. The strength 0.25% indicates the precise concentration of the active ingredient, Timolol Maleate, dissolved in the carrier solution.


Is Ophtim 0.25% a Liquid, a Gel, or an Ointment?

The medication is supplied as a sterile ophthalmic solution, meaning it is a thin, clear liquid designed for direct, topical application to the eye's surface. This formulation is designed to ensure rapid dispersion and consistent delivery of the medicine.

This liquid solution form is different from other formulations, such as gel-forming solutions, which are engineered to thicken on the eye for long-acting effects. As a standard liquid solution, Ophtim 0.25% allows the active drug to be readily absorbed, with the benefit of minimal temporary visual blurring compared to thicker eye ointments. The solution is prepared to be gentle and comfortable when applied.

Regulatory References

  1. in combination
  2. DailyMed

What side effects are possible with Ophtim 0.25%?

Possible Side Effects and Safety Information

The safety profile of Ophtim 0.25% eye drops includes documented adverse reactions that affect the eyes and various major body systems, reflecting systemic absorption of the active ingredient, a beta-adrenergic blocking agent.

Adverse Reactions

The following are documented side effects, categorized by frequency or body system:

Frequency / System Examples of Documented Effects
Common (Ocular) Blurry vision, eye burning/stinging, eye pain, lid edema, keratitis, and hyperaemia.
Systemic (Various) Headache, dizziness, depression, difficulty sleeping, bradycardia (slow heart rate), nausea, dry mouth, and skin rash.

Serious Adverse Reactions and Safety Restrictions

Serious adverse reactions reported in regulatory sources include severe respiratory reactions, such as death due to bronchospasm in patients with asthma, and death associated with cardiac failure. Severe hypotension (low blood pressure) during surgery and bacterial keratitis resulting from contaminated multidose containers have also been documented.

Safety restrictions establish that the medicine is contraindicated (must not be used) in patients with specific, severe conditions, including bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third-degree atrioventricular block, and overt heart failure.

The medicine may also increase symptoms of myasthenia gravis or generalized muscle weakness. Additionally, due to potential additive effects, close observation is necessary when the eye drops are administered alongside oral beta-blocking agents.

Overdose and Emergency Response

A suspected overdose of Ophtim 0.25% (Timolol Maleate) primarily involves systemic effects arising from the action of the non-selective beta-blocker, necessitating immediate medical attention.

Documented Manifestations

Overdose manifestations documented in official regulatory sources center on critical physiological systems. Signs include symptomatic bradycardia (abnormally slow heart rate), hypotension (low blood pressure), and arrhythmia (irregular heartbeat). Respiratory manifestations include bronchospasm and shortness of breath. Central nervous system effects such as dizziness, confusion, and convulsions are also documented. For children, hypoglycemia (low blood sugar) is a specific overdose consideration, as stated in regulatory materials.

Severe Outcomes and Emergency Action

Regulatory information consistently classifies overdose as having the potential for life-threatening outcomes, including progression to cardiac arrest, acute cardiac failure, and high-degree heart block. This documented severity mandates the official instruction to seek immediate medical attention and contact emergency services immediately upon suspected overdose or accidental ingestion.

Supportive Management

The official approach to management is defined as symptomatic and supportive treatment. Procedures listed in regulatory documents include the potential for gastric lavage if the medicine was ingested, and the administration of specific agents such as Atropine sulphate for symptomatic bradycardia. Hospital monitoring is required for observation, which may necessitate an overnight stay due to the potential for delayed systemic effects, noting that Timolol does not readily dialyse.

Therapeutic Uses of Ophtim 0.25%

Ophtim 0.25% is relevant in contexts marked by increased discomfort or tension, specifically targeting clinical settings that involve acute or unstable symptom patterns. Core therapeutic applications include its role in managing conditions like ocular hypertension and open-angle glaucoma.


Relief for Symptoms Related to Heightened Eye Pressure

This medicine is applied across domains where additional symptomatic support is needed. This block is relevant for managing symptoms that interfere with daily comfort, particularly in situations involving certain distressing symptoms. The medicine provides support that helps ease the overall symptom burden and assists with maintaining functional stability during periods of heightened symptoms.

“The medicine helps address symptom clusters that may become intense or disruptive.”


Support for Episodic and Chronic Ocular Conditions

This treatment is commonly used across conditions presenting with episodic or recurrent manifestations, such as open-angle glaucoma. It offers symptomatic relief that helps patients cope more steadily with difficult episodes and supports general well-being by easing the overall symptom load when symptoms become more noticeable.

Quick Fact: Support for Symptom Clusters Ophtim 0.25% is applied when symptoms create noticeable functional strain and require supportive symptom management.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ophtim 0.25%?

Ophtim 0.25% is primarily restricted to the adult population and is contraindicated for several specific groups due to its systemic absorption as a non-selective beta-blocker, according to regulatory labeling.

Classification Official Regulatory Status
Contraindicated Populations Individuals with Bronchial Asthma (or a history of), Severe Chronic Obstructive Pulmonary Disease (COPD), Sinus Bradycardia, Second or Third Degree Atrioventricular (AV) Block, Overt Cardiac Failure, Cardiogenic Shock, or known Hypersensitivity to any component.
Age-Related Limitations Use in pediatric patients (under 18 years) is generally not established; safety and efficacy data are limited for this age group. Use in older adults shows no specific age-related limitations.
Conditional Use Required Use requires caution in patients with conditions like Diabetes Mellitus, First-Degree Heart Block, Myasthenia Gravis, or mild to moderate COPD.
Reproductive Status Pregnant women should use this medicine only if the potential benefit outweighs the risk to the fetus. It is excreted into human milk, requiring a decision to discontinue the drug or discontinue nursing.

These restrictions are based on the potential for the medicine to cause serious systemic effects associated with beta-adrenergic blockade, primarily impacting respiratory and cardiac function.

What should I know about interactions with other medicines?

Ophtim 0.25% (Timolol Maleate) interacts with specific medicinal products primarily through pharmacodynamic and pharmacokinetic mechanisms that require regulatory attention. These patterns are formally documented in government drug labels to manage potential additive systemic effects.

Interaction Type Interacting Agent Categories Official Regulatory Concern
Pharmacodynamic Reinforcement Oral Beta-Blockers, Oral Calcium Channel Blockers, Antiarrhythmics, Catecholamine-Depleting Drugs, Digitalis Glycosides. Risk of marked hypotension, bradycardia, and/or additive beta-blockade effects.
Exposure Modification CYP2D6 Inhibitors (e.g., Quinidine, Fluoxetine, Paroxetine). Potential for potentiated systemic beta-blockade due to reduced clearance and increased plasma exposure.

Interaction-Related Restrictions and Constraints

  • Topical Beta-Blockers: The concomitant administration of two distinct topical beta-adrenergic blocking agents is formally not recommended.
  • Anaesthesia Caution: Physicians overseeing general anaesthesia must be informed of the use of this medicine, as ophthalmic beta-blockers may inhibit the effect of beta-adrenergic agonists during surgical procedures.
  • Timing: When using other concomitant topical eye medications, a separation of administration time is generally advised to ensure optimal absorption and prevent the initial drop from being washed out.

Other officially noted interactions include reports of mydriasis (pupil dilation) with Epinephrine. The regulatory profile focuses on these potentiation effects and administrative constraints; no specific interactions with food, alcohol, or herbal products have been established in certain product monographs.

Mechanism of Action

Non-Selective Blockade of Ocular beta-Adrenergic Receptors

The core mechanism involves the active substance, Timolol Maleate, acting as a competitive antagonist against beta1 and beta2 adrenergic receptors located primarily in the ciliary body epithelium. By blocking these receptors, the drug suppresses the normal nerve signaling (sympathetic stimulation) that regulates the active secretion of aqueous humor by the ciliary body.

Inhibition of the Cellular Fluid Secretion Cascade

The initial receptor blockade initiates the suppression of the downstream cyclic Adenosine Monophosphate (cAMP) signaling pathway. This reduction in the key second messenger directly inhibits the function of active ion transport pumps across the secretory cells, which are required to create the osmotic gradient for fluid movement.

Physiological Effect: Reduced Aqueous Humor Inflow

This complete mechanistic sequence—from receptor blockade to suppressed ion transport—results in the physiological consequence of a reduction in the rate of aqueous humor formation by the ciliary process. The physiological consequence is a direct modulation of the inflow of aqueous humor, resulting in a reduction of the eye's internal fluid volume.

Dosage and Administration Information

How to Use Ophtim 0.25%

The usage of Ophtim 0.25% (Timolol Maleate Ophthalmic Solution) follows specific protocols outlining the correct method, frequency, and duration of administration. This medication is intended for topical ophthalmic administration, meaning it is applied directly to the surface of the affected eye(s) as a sterile liquid solution.

Official Dosing and Frequency

The standard regimen for initiating therapy typically involves administering one drop of the 0.25% concentration twice daily, often scheduled for morning and evening application.

Instruction Detail
Starting Dose One drop (0.25% solution) in the affected eye(s).
Initial Frequency Twice daily.
Maintenance Adjustment May be reduced to once daily administration if the target intraocular pressure is stably maintained.
Pediatric Use For patients aged two years and older, the initial dose is similar: one drop of 0.25% solution twice daily.

Procedural Administration Constraints

Treatment with Ophtim 0.25% is generally part of a long-term therapy protocol to sustain pressure management. When using multiple eye drops, a crucial procedural constraint is required: a minimum interval of at least five minutes must pass between the application of Ophtim 0.25% and any other ophthalmic product. To minimize the amount of medicine absorbed into the body, it is advised to gently close the eyelid or apply light pressure to the tear duct (nasolacrimal occlusion) for one to two minutes after instillation. If a dose is missed, it should be administered as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped.

Recent Clinical Evidence

Research evidence / Overview of studies for Ophtim 0.25%

This section provides an overview of the types of scientific research conducted on Ophtim 0.25% (Timolol Maleate) and what the available data indicate, focusing only on the study structures and findings reported in official sources. This information is descriptive and does not constitute medical advice or predict personal outcomes.


Evidence for use in Ocular Hypertension (OHT)

Research for Ophtim 0.25% in Ocular Hypertension included Randomized Controlled Trials (RCTs) and multi-center efficacy trials, often using double-masked designs to reduce potential bias. Research explored outcomes related to the change in Intraocular Pressure (IOP) across short-term and intermediate follow-up periods in adult populations with elevated eye pressure.

Findings from comparative trials described the relative IOP measurement patterns when the 0.25% solution was tested against non-treatment (placebo) and active control agents. However, comparative evidence for the 0.25% concentration against newer monotherapies is limited, and long-term effects are not fully established by modern, dedicated RCTs beyond one year.


Evidence for use in Open-Angle Glaucoma (OAG)

Studies for Open-Angle Glaucoma (OAG) include multi-center trials and long-term observational follow-up studies, where the latter are often specific to the Timolol drug class. Research examined outcomes related to IOP measurements and maintaining IOP within defined limits, which is the main physiological measure monitored for this condition.

Long-term cohort studies specific to the drug class (Timolol) have described patterns related to the observation of disease progression markers. The data on very long-term clinical outcomes often relies on research from the broader drug class, with limited dedicated modern RCTs specific to the 0.25% concentration.


Research in Special Patient Populations

Ophtim 0.25% was evaluated in studies that primarily involved adult and older adult populations. Regulatory documentation indicates that evidence also exists for the use of this medicine in pediatric populations (children ge 2 years of age). However, subgroup findings are uncertain due to the smaller sample sizes, and there is limited information available for long-term outcomes in these specific groups.

Key Studies & References

  1. Timolol Maleate Ophthalmic Solution Label (NDA 018086) – Indications, Clinical Studies, and Pediatric Use
  2. The Ocular Hypertension Treatment Study: Baseline Factors That Predict the Development of Open-Angle Glaucoma (OHTS Research Group)

Frequently Asked Questions (FAQ)

Common questions about Ophtim 0.25% (FAQ)


Q: What is Ophtim 0.25% used for besides the main condition?

A: In its ophthalmic (eye drop) form, the active substance, Timolol Maleate, is approved primarily for managing ocular hypertension and open-angle glaucoma. According to official information, the systemic (oral) version of Timolol is indicated for other uses, such as treating high blood pressure or preventing certain types of headaches.


Q: How quickly does Ophtim 0.25% start working?

A: Regulatory documents indicate that the effect of Ophtim 0.25% usually begins within 15 to 30 minutes after application. The maximum reduction in internal eye pressure is typically observed within 1 to 5 hours of use.


Q: Is Ophtim 0.25% the same as other brands of the same medicine?

A: Ophtim 0.25% contains the active ingredient Timolol Maleate. Many companies produce approved versions of Timolol Maleate ophthalmic solution, which are officially classified as chemically and therapeutically equivalent. Official regulatory listings often track these equivalent products.


Q: Why is Ophtim 0.25% available in different strengths?

A: The solution is generally available in two strengths, 0.25% and 0.5%. The 0.25% strength is often used when a patient begins therapy. Regulatory documents indicate the higher strength is available for use when the desired therapeutic response is not met with the 0.25% concentration.


Q: What is the difference between Ophtim 0.25% and Ophtim 0.5%?

A: The difference between the two solutions is the concentration of the active ingredient, Timolol Maleate, contained in the solution. The 0.5% solution contains double the concentration of the drug compared to the 0.25% solution. The availability of different strengths allows prescribers to select the concentration appropriate for the necessary level of pressure reduction.


Q: Does Ophtim 0.25% interact with common pain relievers?

A: Official regulatory information lists drug classes known to interact, such as oral beta-blockers, calcium channel blockers, and certain enzyme inhibitors (CYP2D6 inhibitors). Due to the potential for additive systemic effects, regulatory documentation emphasizes that a complete list of all concomitant medications, including over-the-counter products, is required for comprehensive risk assessment.


Q: Can Ophtim 0.25% be used if I wear contact lenses?

A: Standard formulations of this medicine often contain a preservative called benzalkonium chloride, which can be absorbed by soft contact lenses. For this reason, official product information requires the removal of soft contact lenses before instillation of the drops. They may typically be reinserted 15 minutes after the drops have been applied.


Q: How long does the effect of Ophtim 0.25% last after a single use?

A: The therapeutic effect of the medicine on intraocular pressure is generally described in regulatory literature as lasting approximately 24 hours. This duration of effect is consistent with the established regulatory dosing frequency.


Q: Does using Ophtim 0.25% affect driving ability?

A: Official safety documents caution that Timolol eye drops can cause side effects like dizziness, tiredness, and temporary visual disturbances (such as blurred or double vision). Due to these potential effects, regulatory information suggests caution when engaging in activities like driving or operating machinery, particularly when initiating use.


Q: Can I use Ophtim 0.25% after the expiration date?

A: No. The official product labeling mandates that the medication must not be used after the expiration date printed on the packaging. Official regulatory guidance requires that the product not be used past the printed expiration date to maintain quality, potency, and integrity.


Q: Does Ophtim 0.25% have preservatives?

A: The standard multi-dose solution of Timolol Maleate usually contains a preservative, such as benzalkonium chloride, which is listed in the excipients section of the regulatory documents. Preservative-free formulations may also be available, depending on the specific product line.


Q: What should I do if Ophtim 0.25% gets into my mouth or nose?

A: In the event of accidental ingestion of a large amount, regulatory guidelines state that potential symptoms of systemic overdose should be managed by immediately contacting a poison control center or emergency medical services. In cases of accidental exposure, rinsing the affected area is a general measure.


Q: Does Ophtim 0.25% contain gluten or latex?

A: Official excipient lists (inactive ingredients) for Timolol Maleate typically do not include gluten or latex. However, this information is not always explicitly detailed in every regulatory document. For severe allergy concerns, confirming the precise excipients with a pharmacist or healthcare provider is the documented regulatory practice.


Q: Is Ophtim 0.25% available as a generic medicine?

A: Yes, the active ingredient, Timolol Maleate ophthalmic solution, is available as an officially approved generic medicine manufactured by multiple companies, in addition to various specific brand-name products.


Q: Is Ophtim 0.25% linked to any type of eye dryness?

A: Yes, regulatory safety documents and patient information leaflets include the mention of dry eyes among the documented ocular side effects. Other common ocular effects reported include stinging, burning, and itching.


Q: What is the role of Ophtim 0.25% in a full treatment plan?

A: Official indications describe the drug's role as either a monotherapy (used by itself) or as an adjunctive therapy (used alongside other eye drops). Its function is to reduce and maintain healthy intraocular pressure, which is central to managing conditions like ocular hypertension and glaucoma.


Q: Can children use Ophtim 0.25%?

A: Official regulatory documents have established use in children 2 years of age and older. However, official information indicates that clinical oversight is necessary for pediatric use, and treatment parameters are determined by the prescriber. Regulatory documentation notes that long-term safety and efficacy data for this age group are limited.


Q: Are there different storage instructions for opened versus unopened Ophtim 0.25%?

A: Yes, there are distinct instructions. Unopened products must be stored at controlled room temperature and protected from light. Once the bottle is opened, regulatory rules state that multi-dose containers must be discarded after 28 days (1 month).


Q: Why is Ophtim 0.25% sometimes referred to by a different name?

A: The medicine has both a brand name (such as Ophtim) and an internationally recognized generic name for its active ingredient, Timolol Maleate. The existence of multiple brands and the generic name leads to the medicine being referred to by different names in various contexts.


Q: Is the main purpose of Ophtim 0.25% to lower pressure?

A: Yes. According to the official therapeutic indications in regulatory documents, the primary purpose of Ophtim 0.25% (Timolol Maleate) is the reduction of elevated intraocular pressure (IOP) in patients with specific eye conditions.

How should Ophtim 0.25% be stored and disposed of?

Official Storage and Disposal of Ophtim 0.25%

Storage and disposal requirements for Ophtim 0.25% (Timolol Maleate Ophthalmic Solution) are mandated by regulatory agencies to ensure the product's quality and safety.


Storage Conditions

Ophtim 0.25% must be stored at controlled room temperature (20°C to 25°C). It is mandatory to protect the solution from light and it must not be frozen. The bottle must be stored in its original container, kept tightly closed, and remain out of the reach of children.


Stability and Disposal

Multi-dose containers should be discarded 28 days (1 month) after the first opening. Any unused or expired medicine must be disposed of in accordance with local, regional, and national regulations. To protect the environment, the solution must not be emptied into drains or household trash unless specifically instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ophtim 0.25% found in:

A-Z Index: